2型糖尿病合并非酒精性脂肪肝应用利拉鲁肽的疗效观察

Curative Effect of Liraglutide on Type 2 Diabetes Mellitus Combined with Non-alcoholic Fatty Liver Disease

目的:分析2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFLD)应用利拉鲁肽的疗效。方法:选取本院收治的60例T2DM合并NAFLD患者为研究对象,随机分为治疗A组与B组,A组患者接受生活方式干预治疗;在A组基础上,B组接受利拉鲁肽皮下注射治疗。治疗16周后评价疗效及安全性。结果:治疗16周后,治疗B组患者的腰臀比(WHR)、体质量指数(BMI)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、γ-谷氨酰转肽酶(γ-GT)、糖化血红蛋白(HbA1c)、空腹血糖(FPG)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)以及空腹胰岛素(FINS)胰岛素敏感指数(ISI)以及空腹胰岛素(FINS)等指标改善程度显著优于A组(P<0.05)。结论:应用利拉鲁肽治疗T2DM合并NAFLD患者疗效可靠且安全。

Objective:To analyze the curative effect of liraglutideon type 2 diabetes mellitus(T2DM)combined with non-alcoholic fatty liver disease(NAFLD).Methods:60 patients with T2DM and NAFLD who were admitted to the hospital were randomlydivided into group A and group B.Group A was given lifestyle intervention treatment.On the basis of group A,group B was given subcutaneous injection of liraglutide.At 16 weeks after treatment,curative effect and safety were evaluated.Results:After 16 weeks of treatment,improvement degree of WHR,BMI,ALT,AST,γ-GT,HbA1c,FPG,TC,TG,LDL-C,HDL-C,ISI and FINS in group B was significantly better than that in group A(P<0.05).Conclusion:The curative effect of liraglutide on T2DM combined with NAFLD is reliable and safe.